以下文章来源于斑马消费 ，作者范建 斑马消费 . 寻找泛消费领域的斑马企业 作者 | 范建 来源 | 斑马消费 导 语 ：如果该舆情不能妥善处理，对两家公司今年端午节礼销售都将带来不利影响。 再过十几天，就是端午节。最近两天，一个带血的粽子，给正值火热的粽子市场，带来了一层阴 霾。 来伊份的品牌、五芳斋生产的一款蜜枣粽，居然被消费者吃出了一片疑似带血的创可贴。 事发后，这两家上市公司都做出了积极回应，调查暂时没有最终结论，该事件对两家企业在"粽子 季"销售的影响，难以估计。 的粽子 距离端午节只有十多天了，粽子市场经过前期预热，也已渐入佳境。 带血 未曾想，一个疑似"带血的粽子"，给这个中国传统节令食物，蒙上了一层阴影。 5月10日，IP显示为江苏的网友，在社交平台上发布视频称，在给孩子喂食蜜枣粽时，竟然在里面 发现了一个创可贴。 视频记录显示：这个疑似创可贴的异物，呈现出与粽子一样的深色，还有较强的黏连感，上面有较 为清晰的使用过的血污痕迹。 这个问题粽子，并非什么三无产品，而是来自知名休闲零食连锁品牌来伊份，生产商为中国最大的 粽子企业五芳斋。 随着事件在互联网上持续发酵，来伊份（603777.SH）于5 ...

Core Viewpoint - The article discusses the decline and eventual shutdown of the Kaola Haigou app, highlighting its inability to innovate product offerings and compete effectively in the cross-border e-commerce market, particularly against Tmall International [2][6][16]. Group 1: Company History and Transition - Kaola Haigou, originally known as NetEase Kaola, was sold to Alibaba in 2019 and rebranded. The app was officially taken down on March 31, 2025, but signs of its decline were evident much earlier [3][4][6]. - The app's user base and operational team significantly shrank after a major downsizing in October 2021, where the team was reduced from over 400 to just a few dozen [6][7]. Group 2: Market Position and Competition - In Q3 2021, Tmall International surpassed Kaola Haigou with a market share of 37.4% compared to Kaola's 26.0%, indicating a shift in consumer preference [7][8]. - Monthly active users for Kaola Haigou dropped from 7.42 million in July 2020 to 6.44 million by September 2021, reflecting a downward trend in engagement [7][8]. Group 3: Product Offering and Consumer Behavior - The product mix of Kaola Haigou was heavily concentrated on a few categories such as milk powder, diapers, cosmetics, and health products, leading to stagnant growth due to a lack of new offerings [13][14]. - Employees noted that many consumers shifted to Tmall International for better prices, indicating a loss of competitive edge for Kaola Haigou [8][14]. Group 4: Strategic Misalignment - After its acquisition, Kaola Haigou faced strategic misalignment with Tmall International, leading to overlapping services and products, which diluted its unique value proposition [16][18]. - The marketing costs for Kaola Haigou were higher than those for Tmall International, making it difficult to attract and retain users effectively [18][19].

以下文章来源于阿尔法工场DeepFund ，作者基哥 阿尔法工场DeepFund . 专注基金行业事件、产品和人物故事，探究背后的深层逻辑。 作 者 | 基哥 此外，也有消息称"公募基金因沪深300的业绩基准，不断买入金融，最终触发量化的动量因子"； 甚至还出现《保险资金运用管理办法》修订放宽权益类资产风险因子，引发新一轮配置潮的说法。 对此，我们与多位业内人士沟通后，得到了如下判断。 公募背锅？ 来源 | 阿尔法工场DeepFund 导语 ：一次金融板块意外的集体爆发，将量化又一次推上风口浪尖。 近期，在金融板块集体爆发之下，沪指重新站上3400点。 究竟谁在大举买入金融板块？成为了市场关注的焦点。其中，传播最广的是"公募为了业绩基准集 中调仓引发金融板块暴涨"。 之所以外界普遍将昨日金融板块的集体爆发归咎于公募为了业绩基准集中调仓，其逻辑在于《推动 公募基金高质量发展行动方案》（下称《方案》）中指出，对三年以上产品业绩低于业绩比较基准 超过10个百分点的基金经理，要求其绩效薪酬应当明显下降。 同时，现有主动权益基金大多数以沪深300指数作为业绩比较基准。 又是量化？ 既然并非公募集中调仓引发金融板块暴涨， ...

导 语 ： "我并没有真正开始感到衰老，直到我大约90岁的时候。" 阿贝尔，现年62岁，通过伯克希尔哈撒韦公司1999年对位于爱荷华州得梅因市的中美能源公司 （MidAmerican Energy）进行投资加入伯克希尔。 沃伦·巴菲特（Warren Buffett）对于自己究竟是在什么时候决定将伯克希尔·哈撒韦公司（Berkshire Hathaway）的领导权交给格雷格·阿贝尔（Greg Abel），并不能明确指出具体的时间点。 近年来，巴菲特注意到，他指定的接班人每天工作时所展现出的精力是多么充沛。而与之相比，他 自己的工作节奏则明显慢了下来。这两个人在工作的节奏上存在差异，而且这种差异还在不断扩 大。 "没有什么神奇的时刻，"现年94岁的巴菲特在接受WSJ的采访时说。"你怎么能知道自己哪一天变老 了呢？" 伯克希尔的股东和旁观者长期以来一直在思考，谁能接替沃伦·巴菲特这一美国商业和金融界的巨 擘。然而，随着巴菲特迈过90岁生日，他开始体验到一种大多数人在生活中更早就接受的现实：他 的年龄。 "我并没有真正开始感到衰老，出于某种奇怪的原因，直到我大约90岁的时候，"他在内布拉斯加州 奥马哈的办公室通过电话 ...

Group 1: Livestock and Pet Food Industry - The livestock sector is experiencing a supply contraction due to capacity reduction, leading to improved profitability for leading companies like Muyuan Foods, which benefit from scale and efficiency during the new pig cycle [1] - The white feather chicken market faced weak supply and demand, but companies like Shennong Development achieved significant profit reversals in Q1 2025 due to falling feed prices and improved farming efficiency [1] - The core driver of profitability in the livestock sector is the substantial improvement in unit costs, making chicken companies with cost control and channel advantages more attractive for investment [1] - The pet food sector is expected to see both revenue and profit growth in 2024, with profits increasing by 77.8%, driven by lower raw material prices, rapid growth in proprietary brand sales, and steady growth in overseas OEM business [1] - In Q1 2025, the pet food sector remains highly prosperous, but there is significant differentiation among companies; brands like Zhongchong and Guibao are experiencing rapid profit growth, while Petty Holdings faces profit declines due to tariff policy changes and initial investments in new capacity [1] - The seed industry is under pressure, with profits expected to decline by over 50% year-on-year in 2024, and continuing to face challenges in Q1 2025 with an 82.4% year-on-year profit drop [1] - The animal health industry is facing intense competition but is expected to see a rebound in vaccine sales and core product profits starting in Q1 2025, with a projected year-on-year profit increase of 28% [1] - Investment focus should be on leading vaccine companies with stable customer bases and comprehensive product lines, as they are likely to benefit first from downstream recovery and achieve profit restoration [1] Group 2: Medical Aesthetics and Regulatory Environment - The competition in the medical aesthetics sector is intensifying as companies rush to apply for Class III medical device certifications, with certified products expected to become the primary procurement source for downstream institutions [3] - Companies that have obtained Class III certifications and possess industrialization capabilities, such as Haohai Biological and Huaxi Biological, are recommended for their technological barriers and channel synergy advantages, which may lead to rapid profit release during the initial product rollout [3] Group 3: Corporate Restructuring and Market Strategy - Runtian Industrial's plan to "shell" ST United is seen as a strategic move to navigate the current strict IPO review environment, leveraging its profitable consumer assets to enhance the quality and sustainability of the listed company [3] - ST United has been facing continuous losses and cash flow deterioration, with a projected net loss of 63.7 million yuan in 2024, and is under pressure from potential delisting due to ongoing losses and information disclosure violations [3] - Investors are advised to pay close attention to the specific terms of the transaction, including pricing, valuation levels, and profit guarantees, to avoid potential overvaluation or capital manipulation [3] Group 4: Pharmaceutical Innovation and Market Impact - China Antibody Pharmaceutical's recent placement of new shares at an 11% discount aims to raise 124 million HKD, primarily for the development and international collaboration of its innovative drug SM17, indicating the company's strong focus on this project's clinical advancement and commercial potential [4] - SM17 is a first-in-class drug targeting the IL-25 receptor for treating atopic dermatitis, positioned in a rapidly growing market with significant potential for success [4] - The global market for atopic dermatitis patients exceeds 230 million, with over 70 million in China, and if successful, SM17 could rank among the top treatments in this category [4] - Recent acquisitions by major pharmaceutical companies in the early-stage AD candidate market suggest that SM17 could attract interest for cross-border licensing or acquisition if it demonstrates strong data in Phase II trials [4] - The funding allocation for SM17's clinical advancement and international collaboration is set at 45%, with additional funds aimed at expanding the product pipeline and ensuring operational safety [4] Group 5: Impact of U.S. Drug Pricing Policies on Chinese Pharmaceutical Companies - The U.S. administration's recent executive order aims to tie drug prices to the lowest prices in other developed countries, which may indirectly affect Chinese biopharmaceutical companies by creating opportunities for them to enter international markets [5] - While U.S. innovative drug companies may face long-term gross margin pressures due to this pricing policy, Chinese companies with cost advantages could benefit from increased market access [5]

Core Viewpoint - Starbucks is exploring various options for its China business, including the potential sale of a stake, in response to challenges in the market and to optimize its business structure for growth opportunities [1]. Group 1: Business Strategy and Market Position - Starbucks has engaged with private equity firms, tech companies, and other parties to assess its options for the China market, which is its second-largest market [1]. - The company has over 7,750 stores in China, with net revenue of approximately $740 million for the quarter ending March 31, while local competitor Luckin Coffee reported net revenue of $1.2 billion during the same period [1]. - Starbucks is facing macroeconomic and competitive pressures in China, particularly from local brands like Luckin Coffee and Cotti Coffee [1]. Group 2: Future Plans and Market Outlook - Potential bidders are expected to submit initial feedback in the coming weeks, although Starbucks may ultimately decide not to pursue any transaction [2]. - The CEO of Starbucks indicated that after adjusting product offerings and prices, there are signs of improvement in the China market, expressing a commitment to long-term growth in the region [2]. - The company is open to exploring long-term partnerships, similar to strategies employed by McDonald's and Yum! Brands in their China operations [2]. Group 3: Stock Performance - Starbucks' stock has declined by 25% since its peak on February 28 [3].

导 语：今年4月，基金会审计委员会建议对一系列新的举报人指控进行调查，这些指控直指施 瓦布夫妇。 数十年来，克劳斯·施瓦布（Klaus Schwab）在达沃斯（Davos）享有如同皇室般的统治地位。然 而，这种统治在最近一个周五下午戛然而止，因为他点击"发送"按钮，向世界经济论坛（World Economic Forum）受托人发送了一封邮件。 施瓦布似乎正准备从他在半个多世纪前创立的组织优雅退场。然而，2024年，WSJ 的调查揭露了论 坛内部对女性和黑人员工不利的有毒文化，引发广泛关注。 本以为事情会告一段落，但到了 4 月 18 日星期五，基金会审计委员会又建议对一系列新的举报人 指控进行调查，这些指控直指施瓦布及其妻子希尔德（ Hilde ）。 愤怒之下，克劳斯·施瓦布向董事会内部审计委员会发出了包含两段内容的信息，威胁对受托人的职 责履行情况展开调查，并指责他们正在危及组织的未来。 "您有机会在接下来的24小时内撤回您提交给董事会的备忘录，并对质疑我的声誉表达具体的遗 憾，"他的邮件中写道。他还提出了一些建议："为了推动这样的行动，您可以提到我将会提出刑事 诉讼。" "此致，敬礼，"他签署道，"克劳 ...

1 、 《 解读深圳科技金融"25条"新政》摘要 ■ 关注 科技信贷提供商 与 知识产权评估服务商 （如中证信用、国家知识产权运营平台相关企业）， 以及受益的高成长科技公司（生物医药、半导体、人工智能等）。 ■ 利好 创投机构、政府引导基金管理方 （如深创投、深圳高新投），也可能推动更多保险公司（科 技险业务）创新布局。 ■ 深圳有望成为 科技金融基础设施建设和制度创新的领先区域 ，建议关注与 金融科技平台、区域性 数据征信系统、知识产权交易中心 等相关的政策受益标的。 2、 《 中美关税谈判超预期，美线5月舱位几近订满 》 摘要 ■ 5月中旬中美达成超预期的关税协议，取消91%的加征和反制关税，并互相暂停24%的"对等关税"， 这直接打开了一个90天的低税率出口窗口。 ■ 短期内，大量中国出口企业，尤其是面向美国市场的制造商和贸易商开始加速发货，迅速带动了跨 太平洋航线的舱位需求激增。 ■ 尽管早期市场反应有所滞后，但5月13日起"爆舱"现象已经逐步显现，包括马士基、地中海航运等 主要航司都已感受到客户集中下单压力。 ■ 疫情后航运公司普遍对航线运力采取灵活调控策略，从4月起已有多家船司在美线缩减航班、临时 ...

Core Viewpoint - The article discusses the rising trend of using "smart drugs" in high-pressure industries like finance and technology, highlighting both the demand for these drugs and the associated risks of misuse and legal issues [1][2][3]. Group 1: Market Demand and Supply - The first domestic "smart drug" was launched in April, leading to a surge in stock prices for the producing company, Lifan Pharmaceutical, which experienced five consecutive trading limit increases [1][14]. - The global ADHD drug market is projected to reach $14.71 billion by 2025, with a compound annual growth rate of 4.11%, indicating significant market potential for similar drugs [15]. - The only officially approved "smart drug" in China, "Zhuanzhu Da," has faced supply shortages due to high demand and limited production capacity, leading to difficulties for legitimate ADHD patients in obtaining the medication [10][12]. Group 2: Misuse and Legal Issues - Many individuals, particularly young professionals and students, are resorting to illegal means to obtain "smart drugs" like Adderall and Ritalin, often through online channels or underground networks [5][6][7]. - Reports indicate that a significant portion of users are motivated by academic pressures, with some even resorting to virtual currencies for cross-border purchases [6][7]. - The misuse of these drugs can lead to severe health risks, including addiction and various psychological and physical side effects, yet the allure of enhanced focus drives many to overlook these dangers [9][17]. Group 3: Industry Response and Future Outlook - Lifan Pharmaceutical's recent approval of a generic version of "smart drugs" is seen as a response to the supply-demand imbalance in the market, potentially alleviating some of the shortages faced by patients [16][17]. - The company plans to shift packaging operations to its domestic facility to increase supply efficiency, although challenges remain in meeting the high demand [13][17]. - The overall market for "smart drugs" is expected to grow, but the actual therapeutic benefits and risks associated with misuse continue to be a concern for healthcare professionals [17][18].

5月7日，东方尚饮1号SPAC（SPAC.100257）发行申购于当日16时结束。 导 语：李小加提到，滴灌通澳交所目前最重要的任务就是筹集资金，让投资者投资一系列上市 基金产品SPAC。 又有一家SPAC即将登陆滴灌通（澳门）金融资产交易所（下称MCEX或滴灌通澳交所）。 该门店依托高效的机器人臂和智能算法，在保留街区传统特色的同时，顾客可享受快速、精准、健 康的饮品服务。 东方尚饮1号SPAC产品成立于2025年3月20日。截至5月6日，其净资产为人民币20万元，份额净值 人民币1元。 根据MCEX官网介绍，SPAC（Segregated Portfolio Accounts Collective，即特定资产组合投资载 体）是SPAC发起人在MCEX设立的数字化投资载体，类似于"投资公司"。SPAC可用于投资在 MCEX挂牌及其认可的收入分成产品。 SPAC既可以让小微企业在滴灌通澳交所通过收入分成的模式上市融资，也能让广大投资者参与科 技新消费业态获得投资回报。 据了解，东方尚饮1号SPAC所投项目之一，是在MCEX挂牌的SPV尚饮AI智饮能量站-无锡南长街 （SPV.100316）。 SPV（Sing ...